Company Insights

AMWL customer relationships

Explore interactive graphBrowse insights index

AMWL customers relationship map

American Well (AMWL) — customer relationships that drive recurring revenue and platform leverage

Thesis: American Well operates an enterprise telehealth platform, selling the Amwell Platform primarily on multi‑year subscription contracts to payers, health systems and government clients while monetizing professional services and hardware (Carepoint devices) as ancillary revenue streams; the commercial model is concentrated around a small number of large, long‑term customers whose renewals and white‑label arrangements anchor recurring cash flows and product roadmap priorities.

For a concise, investor‑grade map of these customer relationships and what they mean for revenue durability and concentration risk, visit the NullExposure homepage: https://nullexposure.com/

What American Well sells and to whom

American Well’s revenue mix is subscription first (the Amwell Platform), supplemented by professional services and hardware. Contracts are typically three years, often non‑cancelable, and skew to large enterprises and government buyers. These dynamics produce recurring revenue but concentrate downside risk where a handful of payers account for a material share of revenue. The company’s FY2025 decision to divest its psychiatric care business reflects a strategic push to prioritize platform scale and profitability.

Customer roster: who’s on the platform (concise summaries)

  • Defense Health Agency (DHA) — The DHA awarded Amwell a contract that company leadership touted as a validation of the platform’s government capabilities, positioning Amwell as a material federal customer for military health initiatives (Q4 2025 earnings call, March 2026).
  • SOAR — Amwell referenced SOAR as a partner used to manage musculoskeletal (MSK) costs within its ecosystem, illustrating Amwell’s strategy to integrate third‑party clinical vendors into payer programs (Q4 2025 earnings call, March 2026).
  • Avel eCare / Avel eCare, LLC — Amwell sold its Amwell Psychiatric Care business to Avel eCare for roughly $20.7–$21 million in cash, a transaction disclosed in press coverage as part of a focus on core platform growth and cash preservation (news reports, March 2026).
  • Anthem / Anthem Inc. — Amwell historically operates a white‑labeled LiveHealth Online service for Anthem and disclosed Anthem as a major revenue customer in prior SEC filings, underscoring long‑standing payer platform relationships (SEC filing, 2020 S‑1).
  • Cleveland Clinic — The companies launched a joint venture and Cleveland Clinic uses the Amwell Platform for virtual care programs; Cleveland Clinic is a strategic partner and former related‑party customer in regulatory disclosures (Cleveland Clinic press release 2019; SEC filing 2020).
  • Meuhedet — Israel’s Meuhedet HMO implemented the Amwell Platform for a hybrid virtual care program serving over a million members, showing Amwell’s international deployments (SEC filing narrative, FY2020 disclosure).
  • Cerner — Amwell cites Cerner as a technology collaborator that enables direct access to telehealth through EHR interfaces, expanding Amwell’s clinical workflow reach (SEC filing, FY2020 disclosure).
  • Elevance Health (ELV) — Elevance is Amwell’s largest revenue customer and operates LiveHealth Online under a white‑label arrangement; Elevance pays annual subscription and professional services fees, and recent renewals extend this critical relationship (press summaries and earnings commentary, FY2025–FY2026).
  • Blue Cross Blue Shield of Florida (BCBSF) — BCBSF went live on Amwell’s platform in early 2026 as part of a batch of payer renewals the company cited to support recurring revenue stability (Q4 2025 earnings transcript, March 2026).
  • Vida / VIDA — Vida is integrated as a digital companion for specific clinical use cases such as GLP‑1 utilization management, demonstrating Amwell’s ecosystem approach to specialty digital health partners (Q4 2025 earnings call, March 2026).
  • Apple — Apple is cited as an example of an innovator using the Amwell Platform to develop healthcare services, indicating enterprise and device‑level partnerships (SEC filing, FY2020 disclosure).
  • Philips / Philips Holding USA, Inc. — Philips has been a strategic investor and collaborator, working with Amwell on programs including sleep apnea management and related population health initiatives (SEC filing, FY2020 disclosure).
  • Teva Pharmaceuticals (TEVA) — Teva is a related party in Amwell’s disclosures and has contracted for telehealth services, reflecting historical strategic investor and revenue ties (SEC filing, FY2020 disclosure).
  • TytoCare — TytoCare supplies a home exam kit that Amwell integrates into virtual visits, underlining Amwell’s hardware + software value proposition (SEC filing, FY2020 disclosure).
  • CCAW, JV LLC — CCAW is the Cleveland Clinic joint venture in which Amwell holds a minority interest and from which Amwell recognized revenue and made an initial investment (SEC disclosure, FY2020).
  • Epic — Epic is listed among EHR partners that enable Amwell services to be accessed directly through clinician workflows, improving adoption prospects with large health systems (SEC filing, FY2020 disclosure).
  • Intermountain — Intermountain used Amwell to drive digital care adoption inside its system and insurer arm, demonstrating Amwell’s ability to support system‑wide launches (SEC filing, FY2020 disclosure).
  • Nemours — Nemours is referenced as a specialty health system that distributes services enabled by Amwell partnerships, showing reach into pediatric specialties (SEC filing, FY2020 disclosure).
  • Military Health System (MHS) / U.S. Defense Health Agency — Media coverage noted Amwell’s selection to support the MHS digital‑first initiative, reinforcing the company’s government segment wins and public‑sector scale (news coverage, 2023–2026 press mentions).
  • DarioHealth (DRIO) — Public commentary from third parties cites Amwell partnerships supporting payer‑sponsored digital health programs, where firms like DarioHealth note Amwell as a distribution or partner channel for plan relationships (earnings and industry commentary, FY2026).

What these relationships tell investors about AMWL’s operating model

  • Contracting posture: long‑term, subscription anchored. The company sells platform access on three‑year subscription terms with professional services on top, producing predictable recurring revenue and deferred revenue balances. This is a deliberate business design to monetize platform scale.
  • Concentration and criticality. Elevance (LiveHealth Online) is a material revenue anchor, historically representing the largest client share and driving renewal‑sensitive cash flows; top ten customers have comprised the majority of revenue in recent years, creating asymmetric downside if a key payer contract changes.
  • Counterparty mix: large enterprises and government. The customer set skews to health plans, major health systems and government entities (DHA/MHS), which supports stable contract terms but increases procurement complexity and sales cycles.
  • Segment mix and product strategy. Core revenue is software (SaaS subscription) with important complementary revenue from services and hardware (Carepoint devices); divestitures such as the APC sale to Avel eCare reflect a tightening focus on platform economics and margin improvement.
  • Geography and maturity. Revenue is predominantly US‑centric, though Amwell has demonstrated international deployments (e.g., Meuhedet); management frames global work as an expansion opportunity that is subject to local regulation.

Investment implications — distilled

  • Bull case: A durable subscription base with multi‑year payor and government contracts provides recurring revenue and a path to operational leverage if platform adoption broadens across covered lives.
  • Risk case: Revenue concentration (Elevance and other top payers) and reliance on large‑contract renewals create binary outcomes; any significant churn or recalibration in white‑label economics would materially compress cash flows.
  • Catalysts to watch: Renewal cadence with Elevance, DHA/MHS implementation milestones, and integration wins with partners (Vida, SOAR) that translate into measurable utilization gains.

For a deeper, commercial‑grade breakdown of Amwell’s customer relationships and how they feed into subscription economics, explore the full NullExposure coverage at https://nullexposure.com/

Bold takeaways: Amwell is a subscription‑led, enterprise telehealth platform whose revenue durability is anchored in long‑term payer and government contracts, but whose valuation upside is constrained by meaningful customer concentration and execution on platform monetization.

Join our Discord